{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,7]],"date-time":"2026-07-07T14:16:19Z","timestamp":1783433779901,"version":"3.54.6"},"reference-count":74,"publisher":"The Endocrine Society","issue":"1","license":[{"start":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T00:00:00Z","timestamp":1574985600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p>Familial hypercholesterolemia (FH) confers a very high risk of premature cardiovascular disease and is commonly caused by mutations in low-density lipoprotein receptor (LDLR), apolipoprotein B (APOB), or proprotein convertase subtilisin\/kexin type 9 (PCSK9) and very rarely in LDLR adaptor protein 1 (LDLRAP1) genes.<\/jats:p><\/jats:sec><jats:sec><jats:title>Objective<\/jats:title><jats:p>To determine the prevalence of pathogenic mutations in the LDLR, APOB, and PCSK9 in a cohort of subjects who met Simon Broome criteria for FH and compare the clinical characteristics of mutation-positive and mutation-negative subjects.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>Ninety-three men and 107 women aged 19 to 80 years from lipid clinics in the United States and Canada participated. Demographic and historical data were collected, physical examination performed, and serum lipids\/lipoproteins analyzed. Targeted sequencing analyses of LDLR and PCSK9 coding regions and exon 26 of APOB were performed followed by detection of LDLR deletions and duplications.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Disease-causing LDLR and APOB variants were identified in 114 and 6 subjects, respectively. Of the 58 LDLR variants, 8 were novel mutations. Compared with mutation-positive subjects, mutation-negative subjects were older (mean 49 years vs 57 years, respectively) and had a higher proportion of African Americans (1% vs 12.5%), higher prevalence of hypertension (21% vs 46%), and higher serum triglycerides (median 86 mg\/dL vs 122 mg\/dL) levels.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>LDLR mutations were the most common cause of heterozygous FH in this North American cohort. A strikingly high proportion of FH subjects (40%) lacked mutations in known culprit genes. Identification of underlying genetic and environmental factors in mutation-negative patients is important to further our understanding of the metabolic basis of FH and other forms of severe hypercholesterolemia.<\/jats:p><\/jats:sec>","DOI":"10.1210\/jendso\/bvz015","type":"journal-article","created":{"date-parts":[[2019,11,29]],"date-time":"2019-11-29T10:52:43Z","timestamp":1575024763000},"source":"Crossref","is-referenced-by-count":14,"title":["Molecular Characterization of Familial Hypercholesterolemia in a North American Cohort"],"prefix":"10.1210","volume":"4","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7209-6986","authenticated-orcid":false,"given":"Abhimanyu","family":"Garg","sequence":"first","affiliation":[{"name":"Division of Nutrition and Metabolic Diseases, Department of Internal Medicine, UT Southwestern Medical Center, Dallas, Texas"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sergio","family":"Fazio","sequence":"additional","affiliation":[{"name":"Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P Barton","family":"Duell","sequence":"additional","affiliation":[{"name":"Knight Cardiovascular Institute, Oregon Health & Science University, Portland, Oregon"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexis","family":"Baass","sequence":"additional","affiliation":[{"name":"Institut de Recherches Cliniques de Montreal, Montreal, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chandrasekhar","family":"Udata","sequence":"additional","affiliation":[{"name":"Pfizer Inc., San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tenshang","family":"Joh","sequence":"additional","affiliation":[{"name":"Pfizer Inc., San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tom","family":"Riel","sequence":"additional","affiliation":[{"name":"Pfizer Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marina","family":"Sirota","sequence":"additional","affiliation":[{"name":"Pfizer Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Dettling","sequence":"additional","affiliation":[{"name":"Pfizer Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liang","sequence":"additional","affiliation":[{"name":"Pfizer Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pamela D","family":"Garzone","sequence":"additional","affiliation":[{"name":"Pfizer Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barry","family":"Gumbiner","sequence":"additional","affiliation":[{"name":"Pfizer Inc., San Diego, California"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wan","sequence":"additional","affiliation":[{"name":"Pfizer Inc., South San Francisco, California"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"80","published-online":{"date-parts":[[2019,11,29]]},"reference":[{"issue":"4746","key":"2020012008163193200_CIT0001","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1126\/science.3513311","article-title":"A receptor-mediated pathway for cholesterol homeostasis","volume":"232","author":"Brown","year":"1986","journal-title":"Science."},{"issue":"12","key":"2020012008163193200_CIT0002","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1172\/JCI200318925","article-title":"Monogenic hypercholesterolemia: new insights in pathogenesis and treatment","volume":"111","author":"Rader","year":"2003","journal-title":"J Clin Invest."},{"issue":"9","key":"2020012008163193200_CIT0003","doi-asserted-by":"crossref","first-page":"e016461","DOI":"10.1136\/bmjopen-2017-016461","article-title":"Estimating the prevalence of heterozygous familial hypercholesterolaemia: a systematic review and meta-analysis","volume":"7","author":"Akioyamen","year":"2017","journal-title":"BMJ Open."},{"issue":"2","key":"2020012008163193200_CIT0004","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1161\/01.ATV.9.2.211","article-title":"Homozygous familial hypercholesterolemia among French Canadians in Qu\u00e9bec Province","volume":"9","author":"Moorjani","year":"1989","journal-title":"Arteriosclerosis."},{"issue":"2","key":"2020012008163193200_CIT0005","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1097\/MOL.0000000000000487","article-title":"Familial hypercholesterolemia: experience from the French-Canadian population","volume":"29","author":"Paquette","year":"2018","journal-title":"Curr Opin Lipidol."},{"issue":"10","key":"2020012008163193200_CIT0006","doi-asserted-by":"crossref","first-page":"1460","DOI":"10.1161\/01.ATV.13.10.1460","article-title":"Phenotypic variation among familial hypercholesterolemics heterozygous for either one of two Afrikaner founder LDL receptor mutations","volume":"13","author":"Kotze","year":"1993","journal-title":"Arterioscler Thromb."},{"issue":"1","key":"2020012008163193200_CIT0007","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1159\/000175431","article-title":"Experiences with the homozygous cases of familial hypercholesterolemia. A report of 52 patients","volume":"15","author":"Khachadurian","year":"1973","journal-title":"Nutr Metab."},{"issue":"5","key":"2020012008163193200_CIT0008","doi-asserted-by":"crossref","first-page":"1368","DOI":"10.1161\/01.ATV.11.5.1368","article-title":"Serum low density lipoprotein cholesterol level and cholesterol absorption efficiency are influenced by apolipoprotein B and E polymorphism and by the FH-Helsinki mutation of the low density lipoprotein receptor gene in familial hypercholesterolemia","volume":"11","author":"Gylling","year":"1991","journal-title":"Arterioscler Thromb."},{"issue":"1","key":"2020012008163193200_CIT0009","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1399-0004.2007.00915.x","article-title":"Genetic heterogeneity of autosomal dominant hypercholesterolemia","volume":"73","author":"Varret","year":"2008","journal-title":"Clin Genet."},{"issue":"2","key":"2020012008163193200_CIT0010","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1097\/MOL.0000000000000386","article-title":"Complexity of mechanisms among human proprotein convertase subtilisin-kexin type 9 variants","volume":"28","author":"Dron","year":"2017","journal-title":"Curr Opin Lipidol."},{"issue":"8","key":"2020012008163193200_CIT0011","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1016\/S0022-2275(20)42605-7","article-title":"Familial defective apolipoprotein B-100: a mutation of apolipoprotein B that causes hypercholesterolemia","volume":"31","author":"Innerarity","year":"1990","journal-title":"J Lipid Res."},{"issue":"1","key":"2020012008163193200_CIT0012","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.gene.2014.09.020","article-title":"The history of autosomal recessive hypercholesterolemia (ARH). From clinical observations to gene identification","volume":"555","author":"Fellin","year":"2015","journal-title":"Gene."},{"key":"2020012008163193200_CIT0013","first-page":"893","article-title":"Scientific Steering","volume":"303","journal-title":"BMJ"},{"issue":"25","key":"2020012008163193200_CIT0014","first-page":"e1082","article-title":"2018 AHA\/ACC\/AACVPR\/AAPA\/ABC\/ACPM\/ADA\/AGS\/APhA\/ASPC\/NLA\/PCNA guideline on the management of blood cholesterol: A report of the American College of Cardiology\/American Heart Association Task force on clinical practice guidelines","volume":"139","author":"Grundy","year":"2019","journal-title":"Circulation"},{"issue":"2","key":"2020012008163193200_CIT0015","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/0002-9149(93)90155-6","article-title":"Diagnosing heterozygous familial hypercholesterolemia using new practical criteria validated by molecular genetics","volume":"72","author":"Williams","year":"1993","journal-title":"Am J Cardiol."},{"key":"2020012008163193200_CIT0016","first-page":"65","article-title":"Familial","volume-title":"Lipids and Vascular Disease","author":"Defesche","year":"2000"},{"issue":"3 Suppl","key":"2020012008163193200_CIT0017","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/j.jacl.2011.03.452","article-title":"Familial hypercholesterolemias: prevalence, genetics, diagnosis and screening recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia","volume":"5","author":"Hopkins","year":"2011","journal-title":"J Clin Lipidol."},{"issue":"45","key":"2020012008163193200_CIT0018","doi-asserted-by":"crossref","first-page":"3478","DOI":"10.1093\/eurheartj\/eht273","article-title":"Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society","volume":"34","author":"Nordestgaard","year":"2013","journal-title":"Eur Heart J."},{"issue":"9","key":"2020012008163193200_CIT0019","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1016\/j.cjca.2018.05.015","article-title":"Simplified Canadian definition for familial hypercholesterolemia","volume":"34","author":"Ruel","year":"2018","journal-title":"Can J Cardiol."},{"issue":"6","key":"2020012008163193200_CIT0020","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1399-0004.2004.00320.x","article-title":"Cascade genetic screening for familial hypercholesterolemia","volume":"66","author":"Leren","year":"2004","journal-title":"Clin Genet."},{"issue":"18","key":"2020012008163193200_CIT0021","doi-asserted-by":"crossref","first-page":"2240","DOI":"10.1093\/eurheartj\/ehl113","article-title":"Diagnosing familial hypercholesterolaemia: the relevance of genetic testing","volume":"27","author":"van Aalst-Cohen","year":"2006","journal-title":"Eur Heart J."},{"issue":"2","key":"2020012008163193200_CIT0022","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.atherosclerosis.2004.10.011","article-title":"Non-coronary heart disease mortality and risk of fatal cancer in patients with treated heterozygous familial hypercholesterolaemia: a prospective registry study","volume":"179","author":"Neil","year":"2005","journal-title":"Atherosclerosis."},{"issue":"6","key":"2020012008163193200_CIT0023","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1111\/j.1399-0004.2009.01356.x","article-title":"Mutation detection rate and spectrum in familial hypercholesterolaemia patients in the UK pilot cascade project","volume":"77","author":"Taylor","year":"2010","journal-title":"Clin Genet."},{"issue":"9","key":"2020012008163193200_CIT0024","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1016\/j.amjcard.2008.06.056","article-title":"Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia","volume":"102","author":"Civeira","year":"2008","journal-title":"Am J Cardiol."},{"issue":"1","key":"2020012008163193200_CIT0025","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.atherosclerosis.2006.10.003","article-title":"Genetic defects causing familial hypercholesterolaemia: identification of deletions and duplications in the LDL-receptor gene and summary of all mutations found in patients attending the Hammersmith Hospital Lipid Clinic","volume":"194","author":"Tosi","year":"2007","journal-title":"Atherosclerosis."},{"issue":"12","key":"2020012008163193200_CIT0026","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1136\/jmg.2006.038356","article-title":"Genetic causes of familial hypercholesterolaemia in patients in the UK: relation to plasma lipid levels and coronary heart disease risk","volume":"43","author":"Humphries","year":"2006","journal-title":"J Med Genet."},{"issue":"6","key":"2020012008163193200_CIT0027","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1002\/humu.20256","article-title":"Update of the molecular basis of familial hypercholesterolemia in The Netherlands","volume":"26","author":"Fouchier","year":"2005","journal-title":"Hum Mutat."},{"issue":"2","key":"2020012008163193200_CIT0028","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/j.atherosclerosis.2005.02.016","article-title":"Genetic screening protocol for familial hypercholesterolemia which includes splicing defects gives an improved mutation detection rate","volume":"182","author":"Graham","year":"2005","journal-title":"Atherosclerosis."},{"key":"2020012008163193200_CIT0029","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.atherosclerosissup.2017.07.001","article-title":"Familial hypercholesterolemia: The Italian Atherosclerosis Society Network (LIPIGEN)","volume":"29","author":"Averna","year":"2017","journal-title":"Atheroscler Suppl."},{"issue":"2","key":"2020012008163193200_CIT0030","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1097\/MOL.0000000000000496","article-title":"Familial hypercholesterolemia: experience from France","volume":"29","author":"Rab\u00e8s","year":"2018","journal-title":"Curr Opin Lipidol."},{"issue":"4","key":"2020012008163193200_CIT0031","doi-asserted-by":"crossref","first-page":"1704","DOI":"10.1210\/jc.2017-02622","article-title":"A comparative analysis of phenotypic predictors of mutations in familial hypercholesterolemia","volume":"103","author":"Chan","year":"2018","journal-title":"J Clin Endocrinol Metab."},{"issue":"2","key":"2020012008163193200_CIT0032","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.atherosclerosis.2012.07.030","article-title":"Genetic analysis of familial hypercholesterolaemia in Western Australia","volume":"224","author":"Hooper","year":"2012","journal-title":"Atherosclerosis."},{"key":"2020012008163193200_CIT0033","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.atherosclerosis.2016.08.037","article-title":"Clinical characterization and mutation spectrum of German patients with familial hypercholesterolemia","volume":"253","author":"Grenkowitz","year":"2016","journal-title":"Atherosclerosis."},{"issue":"1","key":"2020012008163193200_CIT0034","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.atherosclerosis.2014.11.009","article-title":"Familial hypercholesterolemia in Brazil: cascade screening program, clinical and genetic aspects","volume":"238","author":"Jannes","year":"2015","journal-title":"Atherosclerosis."},{"key":"2020012008163193200_CIT0035","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.atherosclerosis.2016.03.025","article-title":"Efficacy of clinical diagnostic criteria for familial hypercholesterolemia genetic testing in Poland","volume":"249","author":"Mickiewicz","year":"2016","journal-title":"Atherosclerosis."},{"issue":"1","key":"2020012008163193200_CIT0036","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.jacl.2016.11.004","article-title":"Clinical and molecular aspects of familial hypercholesterolemia in Ibero-American countries","volume":"11","author":"Santos","year":"2017","journal-title":"J Clin Lipidol."},{"issue":"Suppl 1","key":"2020012008163193200_CIT0037","doi-asserted-by":"crossref","first-page":"S47","DOI":"10.33549\/physiolres.933587","article-title":"Molecular genetic background of an autosomal dominant hypercholesterolemia in the Czech Republic","volume":"66","author":"Tich\u00fd","year":"2017","journal-title":"Physiol Res."},{"key":"2020012008163193200_CIT0038","author":"ClinVar"},{"key":"2020012008163193200_CIT0039","author":"Leiden Open Variation Database"},{"issue":"Pt 4","key":"2020012008163193200_CIT0040","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1111\/j.1469-1809.2008.00436.x","article-title":"Update and analysis of the University College London low density lipoprotein receptor familial hypercholesterolemia database","volume":"72","author":"Leigh","year":"2008","journal-title":"Ann Hum Genet."},{"issue":"1","key":"2020012008163193200_CIT0041","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.atherosclerosis.2009.02.006","article-title":"Commentary PCSK9 variants: A new database","volume":"203","author":"Leigh","year":"2009","journal-title":"Atherosclerosis."},{"issue":"4","key":"2020012008163193200_CIT0042","doi-asserted-by":"crossref","first-page":"520","DOI":"10.1002\/humu.20882","article-title":"Mutations and polymorphisms in the proprotein convertase subtilisin kexin 9 (PCSK9) gene in cholesterol metabolism and disease","volume":"30","author":"Abifadel","year":"2009","journal-title":"Hum Mutat."},{"issue":"7","key":"2020012008163193200_CIT0043","doi-asserted-by":"crossref","first-page":"E682","DOI":"10.1002\/humu.21002","article-title":"The molecular basis of familial hypercholesterolemia in Lebanon: spectrum of LDLR mutations and role of PCSK9 as a modifier gene","volume":"30","author":"Abifadel","year":"2009","journal-title":"Hum Mutat."},{"key":"2020012008163193200_CIT0044","article-title":"GnomAD"},{"issue":"7","key":"2020012008163193200_CIT0045","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1002\/jcph.867","article-title":"A mechanism-based pharmacokinetic\/pharmacodynamic model for bococizumab, a humanized monoclonal antibody against proprotein convertase subtilisin\/kexin type 9, and its application in early clinical development","volume":"57","author":"Udata","year":"2017","journal-title":"J Clin Pharmacol."},{"issue":"8","key":"2020012008163193200_CIT0046","first-page":"402","article-title":"Molecular characterisation of a low-frequency mutation in exon 8 of the human low-density lipoprotein receptor gene","volume":"76","author":"Kotze","year":"1989","journal-title":"S Afr Med J."},{"issue":"4","key":"2020012008163193200_CIT0047","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1002\/humu.1205","article-title":"Low density lipoprotein receptor (LDLR) gene mutations in Canadian subjects with familial hypercholesterolemia, but not of French descent","volume":"18","author":"Wang","year":"2001","journal-title":"Hum Mutat."},{"issue":"4","key":"2020012008163193200_CIT0048","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1007\/s10038-003-0010-x","article-title":"Familial hypercholesterolemia in Morocco: first report of mutations in the LDL receptor gene","volume":"48","author":"El Messal","year":"2003","journal-title":"J Hum Genet."},{"issue":"3","key":"2020012008163193200_CIT0049","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1111\/j.1399-0004.2006.00585.x","article-title":"Molecular genetic analysis of 1053 Danish individuals with clinical signs of familial hypercholesterolemia","volume":"69","author":"Brusgaard","year":"2006","journal-title":"Clin Genet."},{"issue":"2","key":"2020012008163193200_CIT0050","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1111\/j.1399-0004.1995.tb03926.x","article-title":"Effect of the StuI polymorphism in the LDL receptor gene (Ala 370 to Thr) on lipid levels in healthy individuals","volume":"47","author":"Gudnason","year":"1995","journal-title":"Clin Genet."},{"issue":"1-2","key":"2020012008163193200_CIT0051","first-page":"20","article-title":"Heterozygosity for the missense mutation Ala370\u2013 &gt; Thr in exon 8 of the low density lipoprotein receptor gene does not cause hypercholesterolemia","volume":"3","author":"Weiss","year":"1998","journal-title":"Eur J Med Res."},{"issue":"1","key":"2020012008163193200_CIT0052","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.atherosclerosis.2006.04.014","article-title":"The LDLR variant T705I does not cause the typical phenotype of familial hypercholesterolaemia","volume":"188","author":"Graham","year":"2006","journal-title":"Atherosclerosis."},{"issue":"9","key":"2020012008163193200_CIT0053","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/jmg.37.9.713","article-title":"I705 variant in the low density lipoprotein receptor gene has no effect on plasma cholesterol levels","volume":"37","author":"Heath","year":"2000","journal-title":"J Med Genet."},{"issue":"1","key":"2020012008163193200_CIT0054","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s004390050321","article-title":"The T705I mutation of the low density lipoprotein receptor gene (FH Paris-9) does not cause familial hypercholesterolemia","volume":"99","author":"Lombardi","year":"1997","journal-title":"Hum Genet."},{"key":"2020012008163193200_CIT0055","article-title":"Supplemental Data from: Molecular characterization of familial hypercholesterolemia in a North American cohort","author":"Garg"},{"issue":"3","key":"2020012008163193200_CIT0056","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1086\/500615","article-title":"A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol","volume":"78","author":"Kotowski","year":"2006","journal-title":"Am J Hum Genet."},{"key":"2020012008163193200_CIT0057","doi-asserted-by":"crossref","first-page":"A1372","DOI":"10.1016\/S0735-1097(15)61372-9","article-title":"Initial results from the cascade-FH registry: cascade screening for awareness and detection of familial hypercholesterolemia","volume":"65","author":"O\u2019Brien","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"2020012008163193200_CIT0058","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/j.jacl.2016.07.011","article-title":"US physician practices for diagnosing familial hypercholesterolemia: data from the CASCADE-FH registry","volume":"10","author":"Ahmad","year":"2016","journal-title":"J Clin Lipidol."},{"issue":"12","key":"2020012008163193200_CIT0059","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1161\/ATVBAHA.116.308027","article-title":"Polygenic versus monogenic causes of hypercholesterolemia ascertained clinically","volume":"36","author":"Wang","year":"2016","journal-title":"Arterioscler Thromb Vasc Biol."},{"issue":"6","key":"2020012008163193200_CIT0060","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1161\/CIRCGENETICS.112.963587","article-title":"Low prevalence of mutations in known loci for autosomal dominant hypercholesterolemia in a multiethnic patient cohort","volume":"5","author":"Ahmad","year":"2012","journal-title":"Circ Cardiovasc Genet."},{"issue":"3","key":"2020012008163193200_CIT0061","first-page":"334","article-title":"Treating hyperlipidemia in African Americans","volume":"10","author":"Prisant","year":"2000","journal-title":"Ethn Dis."},{"issue":"4","key":"2020012008163193200_CIT0062","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1172\/JCI114531","article-title":"Common low-density lipoprotein receptor mutations in the French Canadian population","volume":"85","author":"Leitersdorf","year":"1990","journal-title":"J Clin Invest."},{"issue":"5","key":"2020012008163193200_CIT0063","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1111\/j.1469-1809.2012.00724.x","article-title":"Low-density lipoprotein receptor gene familial hypercholesterolemia variant database: update and pathological assessment","volume":"76","author":"Usifo","year":"2012","journal-title":"Ann Hum Genet."},{"issue":"7","key":"2020012008163193200_CIT0064","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1093\/hmg\/ddt573","article-title":"Novel functional APOB mutations outside LDL-binding region causing familial hypercholesterolaemia","volume":"23","author":"Alves","year":"2014","journal-title":"Hum Mol Genet."},{"key":"2020012008163193200_CIT0065","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/j.atherosclerosis.2018.06.819","article-title":"Further evidence of novel APOB mutations as a cause of familial hypercholesterolaemia","volume":"277","author":"Alves","year":"2018","journal-title":"Atherosclerosis."},{"issue":"6","key":"2020012008163193200_CIT0066","first-page":"877","article-title":"Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date","volume":"3","author":"Gaddi","year":"2007","journal-title":"Vasc Health Risk Manag."},{"issue":"19","key":"2020012008163193200_CIT0067","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/j.jacc.2008.06.050","article-title":"Frequency of low-density lipoprotein receptor gene mutations in patients with a clinical diagnosis of familial combined hyperlipidemia in a clinical setting","volume":"52","author":"Civeira","year":"2008","journal-title":"J Am Coll Cardiol."},{"issue":"24","key":"2020012008163193200_CIT0068","doi-asserted-by":"crossref","first-page":"2403","DOI":"10.1161\/CIRCULATIONAHA.113.001592","article-title":"Serum proprotein convertase subtilisin\/kexin type 9 and cell surface low-density lipoprotein receptor: evidence for a reciprocal regulation","volume":"127","author":"Tavori","year":"2013","journal-title":"Circulation."},{"issue":"2","key":"2020012008163193200_CIT0069","doi-asserted-by":"crossref","first-page":"e000028","DOI":"10.1161\/JAHA.112.000028","article-title":"Elevated PCSK9 levels in untreated patients with heterozygous or homozygous familial hypercholesterolemia and the response to high-dose statin therapy","volume":"2","author":"Raal","year":"2013","journal-title":"J Am Heart Assoc."},{"issue":"22","key":"2020012008163193200_CIT0070","doi-asserted-by":"crossref","first-page":"2167","DOI":"10.1161\/CIR.0000000000000297","article-title":"The Agenda for familial hypercholesterolemia: A scientific statement from the American Heart Association","volume":"132","author":"Gidding","year":"2015","journal-title":"Circulation."},{"issue":"22","key":"2020012008163193200_CIT0071","doi-asserted-by":"crossref","first-page":"2578","DOI":"10.1016\/j.jacc.2016.03.520","article-title":"Diagnostic yield and clinical utility of sequencing familial hypercholesterolemia genes in patients with severe hypercholesterolemia","volume":"67","author":"Khera","year":"2016","journal-title":"J Am Coll Cardiol."},{"issue":"6","key":"2020012008163193200_CIT0072","doi-asserted-by":"crossref","first-page":"662","DOI":"10.1016\/j.jacc.2018.05.044","article-title":"Clinical genetic testing for familial hypercholesterolemia: JACC Scientific Expert Panel","volume":"72","author":"Sturm","year":"2018","journal-title":"J Am Coll Cardiol."},{"issue":"3","key":"2020012008163193200_CIT0073","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1161\/CIRCGENETICS.111.962456","article-title":"Discriminative ability of LDL-cholesterol to identify patients with familial hypercholesterolemia: a cross-sectional study in 26,406 individuals tested for genetic FH","volume":"5","author":"Huijgen","year":"2012","journal-title":"Circ Cardiovasc Genet."},{"issue":"9874","key":"2020012008163193200_CIT0074","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0140-6736(12)62127-8","article-title":"Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study","volume":"381","author":"Talmud","year":"2013","journal-title":"Lancet."}],"container-title":["Journal of the Endocrine Society"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/jes\/advance-article-pdf\/doi\/10.1210\/jendso\/bvz015\/31154155\/bvz015.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jes\/article-pdf\/4\/1\/bvz015\/31885003\/bvz015.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/jes\/article-pdf\/4\/1\/bvz015\/31885003\/bvz015.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,7]],"date-time":"2021-02-07T17:58:44Z","timestamp":1612720724000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jes\/article\/doi\/10.1210\/jendso\/bvz015\/5645712"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,29]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1,1]]}},"URL":"https:\/\/doi.org\/10.1210\/jendso\/bvz015","relation":{},"ISSN":["2472-1972"],"issn-type":[{"value":"2472-1972","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,1]]},"published":{"date-parts":[[2019,11,29]]},"article-number":"bvz015"}}